Treatment of Sodium Retention in Liver Cirrhosis With Dexamethasone
- Registration Number
- NCT01311167
- Lead Sponsor
- Insel Gruppe AG, University Hospital Bern
- Brief Summary
Accumulation of salt and water in patients with liver disease (so called liver cirrhosis) is possibly related to the increased effect of steroid hormones on salt reabsorption in the kidney. By reducing overall steroid production with the dexamethasone the accumulation of salt and water could be prevented.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 2
Inclusion Criteria
- patients with established liver cirrhosis (biopsy or biochemically)
- hepatorenal syndrome type 1 or 2 (with a serum creatinin >175 umol/l)
- age between 18 and 75
- no bacterial infection
- no cardiovascular or extrahepatic disease (end of life)
- no structural kidney disease
- no hepatocellular carcinoma
Read More
Exclusion Criteria
- age under 15 or over 75
- treatment with corticosteroids (dexamethasone included)
- bacterial infection
- cardiovascular or extrahepatic disease (end of life)
- structural kidney disease (indicated by hematuria, proteinuria)
- hepatocellular carcinoma
- mental disability
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Dexamethasone Dexamethasone - Placebo Placebo -
- Primary Outcome Measures
Name Time Method Daily sodium excretion of sodium in the urine 4 days
- Secondary Outcome Measures
Name Time Method Daily potassium excretion 4 days weight reduction 4 days Reduction of doses of diuretics 4 days Reduction of ascites 4 days Reduction of cortisol excretion in the urine 4 days Reduction of cortisol levels in the urine 4 days
Trial Locations
- Locations (3)
University Hospital Lausanne
🇨ðŸ‡Lausanne, Vaud, Switzerland
University Hospital Inselspital
🇨ðŸ‡Bern, Switzerland
University Hospital Geneva
🇨ðŸ‡Geneva, Switzerland